RINVOQ is a Janus kinase (JAK) inhibitor indicated for the treatment of:
*Adults with moderately to severely active rheumatoid arthritis who have
had an inadequate response or intolerance to one or more TNF blockers.
*Adults with active psoriatic arthritis who have had an inadequate response
or intolerance to one or more TNF blockers.
*Adults and pediatric patients 12 years of age and older with refractory,
moderate to severe atopic dermatitis whose disease is not adequately
controlled with other systemic drug products, including biologics, or when
use of those therapies are inadvisable.
*Adults with moderately to severely active ulcerative colitis who have had
an inadequate response or intolerance to one or more TNF blockers.
*Adults with active ankylosing spondylitis who have had an inadequate
response or intolerance to one or more TNF blockers.
